journal article·2023-12-12Open access

New Perspective for Using Antimicrobial and Cell-Penetrating Peptides to Increase Efficacy of Antineoplastic 5-FU in Cancer Cells

Nuno Vale, Eduarda Ribeiro, Inês Cruz, Valentina Stulberg, Beate Koksch, Bárbara Costa

Journal of Functional Biomaterials· Volume 14· Issue 12

Abstract

This study explores the effectiveness of the antineoplastic agent 5-FU in cancer cells by leveraging the unique properties of cationic antimicrobial peptides (CAMPs) and cell-penetrating peptides (CPPs). Traditional anticancer therapies face substantial limitations, including unfavorable pharmacokinetic profiles and inadequate specificity for tumor sites. These drawbacks often necessitate higher therapeutic agent doses, leading to severe toxicity in normal cells and adverse side effects. Peptides have emerged as promising carriers for targeted drug delivery, with their ability to selectively deliver therapeutics to cells expressing specific receptors. This enhances intracellular drug delivery, minimizes drug resistance, and reduces toxicity. In this research, we comprehensively evaluate the ADMET (absorption, distribution, metabolism, excretion, and toxicity) properties of various AMPs and CPPs to gain insights into their potential as anticancer agents. The peptide synthesis involved a solid-phase synthesis using a Liberty Microwave Peptide Synthesizer. The peptide purity was confirmed via LC-MS and HPLC methods. For the ADMET screening, computational tools were employed, assessing parameters like absorption, distribution, metabolism, excretion, and toxicity. The cell lines A549 and UM-UC-5 were cultured and treated with 5-FU, CAMPs, and CPPs. The cell viability was measured using the MTT assay. The physicochemical properties analysis revealed favorable drug-likeness attributes. The peptides exhibited potential inhibitory activity against CYP3A4. The ADMET predictions indicated variable absorption and distribution characteristics. Furthermore, we assessed the effectiveness of these peptides alone and in combination with 5-FU, a widely used antineoplastic agent, in two distinct cancer cell lines, UM-UC-5 and A549. Our findings indicate that CAMPs can significantly reduce the cell viability in A549 cells, while CPPs exhibit promising results in UM-UC-5 cells. Understanding these multifaceted effects could open new avenues for antiviral and anticancer research. Further, experimental validation is necessary to confirm the mechanism of action of these peptides, especially in combination with 5-FU.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Antimicrobial Peptides and Activities · RNA Interference and Gene Delivery · Peptidase Inhibition and Analysis

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

PerMed Research Group, Center for Health Technology and Services Research (CINTESIS), Rua Doutor Plácido da Costa, 4200-450 Porto, Portugal

CINTESIS@RISE, Faculty of Medicine, University of Porto, Alameda Hernâni Monteiro, 4200-319 Porto, Portugal

Department of Community Medicine, Health Information and Decision (MEDCIDS), Faculty of Medicine, University of Porto, Rua Doutor Plácido da Costa, 4200-450 Porto, Portugal

ICBAS—School of Medicine and Biomedical Sciences, University of Porto, Rua Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal

Institute of Chemistry and Biochemistry, Freie Universität Berlin, Arnimallee 20, 14195 Berlin, Germany

Funding

FEDER—Fundo Europeu de Desenvolimento Regional through the COMPETE 2020—Operational Programme for Competitiveness and Internationalization (POCI), Portugal 2020, and by Portuguese funds through FCT—Fundação para a Ciência e a Tecnologia · FCT and FEDER (European Union)

References (46)

Show source-provided references
1. De Martini, L.B., Sulmona, C., Brambilla, L., and Rossi, D. (2023). Cell-Penetrating Peptides as Valuable Tools for Nose-to-Brain Delivery of Biological Drugs. Cells, 12.10.3390/cells12121643 ↗
2. Peptide-Based Supramolecular Hydrogels for Local Drug Delivery10.1016/j.addr.2021.05.010 ↗
3. Recent Developments in Anticancer Drug Delivery Using Cell Penetrating and Tumor Targeting Peptides10.1016/j.jconrel.2017.02.006 ↗
4. Controlled Drug Delivery Vehicles for Cancer Treatment and Their Performance10.1038/s41392-017-0004-3 ↗
5. Li, C.M., Haratipour, P., Lingeman, R.G., Perry, J.J.P., Gu, L., Hickey, R.J., and Malkas, L.H. (2021). Novel Peptide Therapeutic Approaches for Cancer Treatment. Cells, 10.10.3390/cells10112908 ↗
6. Lindberg, J., Nilvebrant, J., Nygren, P.-Å., and Lehmann, F. (2021). Progress and Future Directions with Peptide-Drug Conjugates for Targeted Cancer Therapy. Molecules, 26.10.3390/molecules26196042 ↗
7. Cell-Penetrating Peptides: From Basic Research to Clinics10.1016/j.tips.2017.01.003 ↗
8. Peptide–Drug Conjugate-Based Novel Molecular Drug Delivery System in Cancer10.1016/j.tips.2021.07.001 ↗
9. The Role of Cell-penetrating Peptides in Potential Anti-cancer Therapy10.1002/ctm2.822 ↗
10. A Peptide for Transcellular Cargo Delivery: Structure-Function Relationship and Mechanism of Action10.1016/j.jconrel.2020.05.030 ↗
11. Ghaly, G., Tallima, H., Dabbish, E., ElDin, N.B., El-Rahman, M.K.A., Ibrahim, M.A.A., and Shoeib, T. (2023). Anti-Cancer Peptides: Status and Future Prospects. Molecules, 28.10.3390/molecules28031148 ↗
12. Yang, M., Liu, S., and Zhang, C. (2023). Antimicrobial Peptides with Antiviral and Anticancer Properties and Their Modification and Nanodelivery Systems. Curr. Res. Biotechnol., 5.10.1016/j.crbiot.2023.100121 ↗
13. Tornesello, A.L., Borrelli, A., Buonaguro, L., Buonaguro, F.M., and Tornesello, M.L. (2020). Antimicrobial Peptides as Anticancer Agents: Functional Properties and Biological Activities. Molecules, 25.10.3390/molecules25122850 ↗
14. Lyu, Z., Yang, P., Lei, J., and Zhao, J. (2023). Biological Function of Antimicrobial Peptides on Suppressing Pathogens and Improving Host Immunity. Antibiotics, 12.10.3390/antibiotics12061037 ↗
15. Răileanu, M., and Bacalum, M. (2023). Cancer Wars: Revenge of the AMPs (Antimicrobial Peptides), a New Strategy against Colorectal Cancer. Toxins, 15.10.3390/toxins15070459 ↗
16. Antimicrobial Peptide-Based Materials: Opportunities and Challenges10.1039/D1TB02617H ↗
17. Clinical Applications and Anticancer Effects of Antimicrobial Peptides: From Bench to Bedside10.3389/fonc.2022.819563 ↗
18. Cell-Penetrating Peptides: Possible Transduction Mechanisms and Therapeutic Applications10.3892/br.2016.639 ↗
19. Penetrating Peptides: Applications in Drug Delivery10.1016/j.jddst.2023.104475 ↗
20. Drug Combination and Repurposing for Cancer Therapy: The Example of Breast Cancer10.1016/j.heliyon.2021.e05948 ↗
21. Gilad, Y., Gellerman, G., Lonard, D.M., and O’Malley, B.W. (2021). Drug Combination in Cancer Treatment—From Cocktails to Conjugated Combinations. Cancers, 13.10.3390/cancers13040669 ↗
22. Overcoming Cancer Therapeutic Bottleneck by Drug Repurposing10.1038/s41392-020-00213-8 ↗
23. Vale, N., Pereira, M., Santos, J., Moura, C., Marques, L., and Duarte, D. (2022). Prediction of Drug Synergism between Peptides and Antineoplastic Drugs Paclitaxel, 5-Fluorouracil, and Doxorubicin Using In Silico Approaches. Int. J. Mol. Sci., 24.10.3390/ijms24010069 ↗
24. Duarte, D., and Vale, N. (2021). Synergistic Interaction of CPP2 Coupled with Thiazole Derivates Combined with Clotrimazole and Antineoplastic Drugs in Prostate and Colon Cancer Cell Lines. Int. J. Mol. Sci., 22.10.3390/ijms222111984 ↗
25. SYNPRED: Prediction of Drug Combination Effects in Cancer Using Different Synergy Metrics and Ensemble Learning10.1093/gigascience/giac087 ↗
26. Cancer Chemotherapy and beyond: Current Status, Drug Candidates, Associated Risks and Progress in Targeted Therapeutics10.1016/j.gendis.2022.02.007 ↗
27. Potent Cationic Antimicrobial Peptides against Mycobacterium Tuberculosis in Vitro10.1016/j.jgar.2019.04.018 ↗
28. Targeting Mycobacterium Tuberculosis and Other Microbial Pathogens Using Improved Synthetic Antibacterial Peptides10.1128/AAC.00175-13 ↗
29. (2023, September 04). Available online: https://admetmesh.scbdd.com/.
30. ADMETlab 2.0: An Integrated Online Platform for Accurate and Comprehensive Predictions of ADMET Properties10.1093/nar/gkab255 ↗
31. Ghosh, J., Lawless, M.S., Waldman, M., Gombar, V., and Fraczkiewicz, R. (2016). Silico Methods for Predicting Drug Toxicity, Humana.
32. Evaluation of ADMET Predictor in Early Discovery Drug Metabolism and Pharmacokinetics Project Work10.1124/dmd.121.000552 ↗
33. Cyclic Peptide Natural Products Chart the Frontier of Oral Bioavailability in the Pursuit of Undruggable Targets10.1016/j.cbpa.2017.04.012 ↗
34. Doll, C., Bestendonk, C., Kreutzer, K., Neumann, K., Pohrt, A., Trzpis, I., Koerdt, S., Dommerich, S., Heiland, M., and Raguse, J.-D. (2021). Prognostic Significance of Estrogen Receptor Alpha in Oral Squamous Cell Carcinoma. Cancers, 13.10.3390/cancers13225763 ↗
35. The Role of Estrogen Receptors in Urothelial Cancer10.3389/fendo.2021.643870 ↗
36. Estrogen Receptor Beta Promotes Lung Cancer Invasion via Increasing CXCR4 Expression10.1038/s41419-022-04514-4 ↗
37. Estrogen Receptors Promote NSCLC Progression by Modulating the Membrane Receptor Signaling Network: A Systems Biology Perspective10.1186/s12967-019-2056-3 ↗
38. Balraj, S., Selvam, P., Pommier, Y., Metifiot, M., Christophe, M., Pannecouque, C., and De Clercq, E. (2014). Investigation of Anti-HIV Activity, Cytotoxicity and HIV Integrase Inhibitory Activity of Polyherbal Formulation BH Extracts. BMC Infect. Dis., 14.10.1186/1471-2334-14-S3-O23 ↗
39. Sala, M., Spensiero, A., Esposito, F., Scala, M.C., Vernieri, E., Bertamino, A., Manfra, M., Carotenuto, A., Grieco, P., and Novellino, E. (2016). Development and Identification of a Novel Anti-HIV-1 Peptide Derived by Modification of the N-Terminal Domain of HIV-1 Integrase. Front. Microbiol., 7.10.3389/fmicb.2016.00845 ↗
40. Development and Evaluation of Peptide-Functionalized Gold Nanoparticles for HIV Integrase Inhibition10.1007/s10989-018-9673-1 ↗
41. Integrase Strand Transfer Inhibitor Use and Cancer Incidence in a Large Cohort Setting10.1093/ofid/ofac029 ↗
42. HIV-1 Integrase Inhibitors with Modifications That Affect Their Potencies against Drug Resistant Integrase Mutants10.1021/acsinfecdis.0c00819 ↗
43. Future of 5-Fluorouracil in Cancer Therapeutics, Current Pharmacokinetics Issues and a Way Forward10.4103/JCRP.JCRP_10_19 ↗
44. Selenium Nanoparticles as a Carrier of 5-Fluorouracil to Achieve Anticancer Synergism10.1021/nn202452c ↗
45. Cetuximab Functionalization Strategy for Combining Active Targeting and Antimigration Capacities of a Hybrid Composite Nanoplatform Applied to Deliver 5-Fluorouracil: Toward Colorectal Cancer Treatment10.1039/D0BM01904F ↗
46. Samec, T., Boulos, J., Gilmore, S., Hazelton, A., and Alexander-Bryant, A. (2022). Peptide-Based Delivery of Therapeutics in Cancer Treatment. Mater. Today Bio, 14.10.1016/j.mtbio.2022.100248 ↗